Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

966
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
966
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

402
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
402
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

369
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
369

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Beyond the Tricuspid Envelope: The Utility of TAPSE × PAAT in Advanced Heart Failure".

Echocardiography (Mount Kisco, N.Y.)·2026
Same author

Evaluation of left intraventricular flow dynamics using the novel non-contrast HyperDoppler technique.

European heart journal. Imaging methods and practice·2026
Same author

Quantitative susceptibility mapping in myotonic dystrophy: clinical relevance of subcortical iron accumulation.

Brain communications·2026
Same author

Nutritional Regulation of Cardiac Metabolism and Function: Molecular and Epigenetic Mechanisms and Their Role in Cardiovascular Disease Prevention.

Nutrients·2026
Same author

Prescriptive appropriateness of echocardiography for the diagnosis of infective endocarditis: an 11-year observational study.

European heart journal. Cardiovascular Imaging·2025
Same author

Adipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia.

Cell death & disease·2025

Related Experiment Video

Updated: Feb 14, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K

[Heart failure with mid-range ejection fraction. Looking for Middle Earth?]

Donato Mele1, Giovanni Andrea Luisi1, Marianna Nardozza1

  • 1Centro Cardiologico Universitario e LTTA Centre, Università degli Studi, Ferrara.

Giornale Italiano Di Cardiologia (2006)
|February 17, 2018
PubMed
Summary

The European Society of Cardiology classifies heart failure by left ventricular ejection fraction (LVEF). This article examines the characteristics and prognosis of the mid-range LVEF group, questioning its distinct category status.

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

Related Experiment Videos

Last Updated: Feb 14, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.1K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.4K

Area of Science:

  • Cardiology
  • Heart Failure Research

Background:

  • The European Society of Cardiology (ESC) updated heart failure (HF) classification based on left ventricular ejection fraction (LVEF).
  • Three categories are defined: HF with preserved EF (HFpEF, LVEF ≥50%), mid-range EF (HFmrEF, LVEF 40-49%), and reduced EF (HFrEF, LVEF <40%).
  • The HFmrEF category's distinctness is debated, with uncertainty if it's a separate entity or a transitional phase.

Purpose of the Study:

  • To critically evaluate the current evidence regarding the characteristics and prognosis of heart failure with mid-range ejection fraction (HFmrEF).
  • To discuss the clinical significance and independent classification of the HFmrEF group within the broader heart failure spectrum.

Main Methods:

  • Review and synthesis of existing scientific literature and clinical studies on heart failure classification.
  • Analysis of data pertaining to patient demographics, clinical presentation, treatment response, and outcomes in the HFmrEF population.
  • Comparison of HFmrEF characteristics and prognosis against HFpEF and HFrEF groups.

Main Results:

  • Evidence suggests HFmrEF may represent a distinct clinical entity with unique pathophysiological features.
  • Prognostic data indicate outcomes for HFmrEF patients may differ from both HFpEF and HFrEF, though variability exists.
  • Further research is needed to fully elucidate the independent nature and optimal management strategies for HFmrEF.

Conclusions:

  • The HFmrEF classification presents a challenge in distinguishing it as a truly independent category from HFpEF and HFrEF.
  • Current evidence supports HFmrEF as a potentially distinct group requiring further investigation for tailored therapeutic approaches.
  • Clarifying the HFmrEF category is crucial for refining heart failure diagnosis, management, and improving patient outcomes.